[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354332-105":59,"doc-detail-354332-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exosomes-in-ovarian-cancer-promoters-biomarkers-and-therapeutic-targets","Exosomes in Ovarian Cancer: Promoters, Biomarkers, and Therapeutic Targets","","Ovarian cancer is an aggressive malignancy with high recurrence and platinum resistance that drive poor prognosis. Early screening can improve survival, yet high-precision biomarkers remain limited. Exosomes are nanoscale vesicles that mediate intercellular communication by transferring bioactive cargo, with composition reflecting pathological states. Their structural stability supports efficient non-invasive early screening, and engineered exosomes may improve drug-delivery specificity while reducing toxic adverse reactions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exosomes-in-ovarian-cancer-promoters-biomarkers-and-therapeutic-targets/354332/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exosomes-in-ovarian-cancer-promoters-biomarkers-and-therapeutic-targets/354332.png","ImageObject",300,407,{"name":92,"@type":93},"Elsa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does ovarian cancer have poor prognosis?","Question",{"text":112,"@type":113},"High recurrence and platinum resistance contribute to poor outcomes. Late diagnosis is also a major reason patients present with advanced-stage disease.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can exosomes support early screening in ovarian cancer?",{"text":117,"@type":113},"Exosomes are nanoscale vesicles with stable structures, and their bioactive composition can reflect pathological states, enabling efficient non-invasive screening.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the therapeutic advantage of engineered exosomes?",{"text":121,"@type":113},"Engineered exosomes can enhance delivery specificity for clinical pharmacotherapy and help reduce adverse toxic reactions compared with less effective conventional approaches.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354332,1790173338,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","International Journal of Nanomedicine  \nOpen Access Full Text Article REVIEW  \nExosomes in Ovarian Cancer: Promoters, Biomarkers, and Therapeutic Targets  \nFengyi Wang 1 , Haiyan Dong2 , Yuli Song 1 , Yi Zhang 1  \n1Department of Gynecology, The First Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of China; 2Department of Gynecology, Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, People’s Republic of China  \nCorrespondence: Yi Zhang, Email [syzi@163.com](syzi@163.com)  \n\n| Abstract: Ovarian cancer is an aggressive malignancy treated primarily with surgery and platinum-based chemotherapy. The high recurrence rate and platinum resistance are the primary reasons for poor prognosis in ovarian cancer. Early screening can improve patient survival, but there are currently no high-precision biomarkers available. Exosomes are nanoscale vesicles that mediate intercellular communication by transferring bioactive molecules, and their composition reflects pathological states. Late diagnosis is the primary cause of poor prognosis in patients with ovarian cancer. Owing to the high stability conferred by their unique structure, exosomes can serve as an efficient, non-invasive approach for early screening. In the context of drug delivery, engineered exosomes using novel advanced technologies can enhance the specificity of clinical pharmacotherapy and reduce adverse toxic reactions. This review summarizes the latest research findings on ovarian cancer-related exosomes and introduces their important roles in exploring the mechanisms of ovarian cancer progression, metastasis, and chemoresistance, as well as their potential as prognostic biomarkers and therapeutic targets.\u003Cbr>Keywords: exosomes, ovarian cancer, extracellular vesicles, cancer metastasis, chemoresistance, biomarker, engineered exosomes |\n| --- |\n| Introduction\u003Cbr>Ovarian cancer (OC) is one of the common malignant tumors in the female reproductive system, and its disease burden continues to increase globally. Epidemiological data indicate that OC ranks eighth among female malignancies in terms of both mortality and incidence, with more than 207,000 women dying from ovarian cancer worldwide each year.1 In 2020, there were over 310,000 new cases and approximately 200,000 deaths.2 Metastasis of primary OC can occur through three pathways: peritoneal implantation, lymphatic metastasis, and hematogenous metastasis,3 among which peritoneal implantation is the most common. 90% of patients with advanced ovarian cancer develop peritoneal carcinomatosis and excessive intra-abdominal fluid known as malignant ascites.4\u003Cbr>Nowadays, with the continuous advancement of medicine, the treatment of ovarian cancer is no longer limited to simple surgical resection of lesions, but has gradually developed into more precise application of refined surgery combined with comprehensive approaches such as platinum-based chemotherapy, immunotherapy, and targeted therapy.5 Although modern treatment methods such as bevacizumab and poly (ADP-ribose) polymerase (PARP) inhibitors have significantly improved patient survival,6 OC still has the highest mortality rate among all gynecological malignancies due to the high recurrence rate after resection and widespread chemoresistance.5 Since ovarian cancer has no obvious symptoms in the early stage, most patients are already in the advanced stage (stage III or IV) when they seek medical treatment, with a 5-year survival rate of less than 40% .7 Early diagnosis helps to improve patient survival. Therefore, exploring new therapeutic directions and biomarkers is crucial for improving the prognosis of OC patients. Cancer nanomedicine employs nanotechnology to deliver therapeutic agents—including nucleic acids, proteins, and small-molecule drugs—to tumor tissues. In cancer immunotherapy, nanoscale drug delivery systems offer superior safety and efficacy compared with conventional antineoplastic therapies.8 Conventional nanop","cbCaio4JGzF3dwIr","https://ap.wps.com/l/cbCaio4JGzF3dwIr","pdf",4233476,24,"English","# Abstract\n# Introduction\n## Ovarian cancer burden and metastasis routes\n## Current treatment strategies and unmet needs\n## Nanomedicine and drug delivery background\n## Conventional nanoparticles vs. exosomes","[{\"question\":\"Why does ovarian cancer have poor prognosis?\",\"answer\":\"High recurrence and platinum resistance contribute to poor outcomes. Late diagnosis is also a major reason patients present with advanced-stage disease.\"},{\"question\":\"How can exosomes support early screening in ovarian cancer?\",\"answer\":\"Exosomes are nanoscale vesicles with stable structures, and their bioactive composition can reflect pathological states, enabling efficient non-invasive screening.\"},{\"question\":\"What is the therapeutic advantage of engineered exosomes?\",\"answer\":\"Engineered exosomes can enhance delivery specificity for clinical pharmacotherapy and help reduce adverse toxic reactions compared with less effective conventional approaches.\"}]","Exosomes in Ovarian Cancer: Promoters, Biomarkers, and Therapeutic Targets | PDF",1790110153]